Picture this: a patient with a rare kidney disorder receives specialized nutrition therapy at home instead of spending another week in a hospital bed. Across town, a cardiologist implants a leadless device smaller than a AAA battery directly into a patient’s heart through a catheter, no chest incision required. Meanwhile, in a lab setting, an AI platform screens three trillion synthesizable compounds in weeks to find a drug candidate that might have taken years to identify manually. These aren’t predictions. They’re happening right now, driven by companies like Pentec Health, Abbott, and Atomwise, each reshaping their corners of healthcare at a pace that deserves a closer look.
What Pentec Health Actually Does and Why It Matters
Pentec Health isn’t a household name, but for patients living with chronic kidney disease, rare metabolic disorders, chronic pain, or complex gastrointestinal conditions, it might be the most important care provider they’ve never heard of.
Founded in 1983 and headquartered in Boothwyn, Pennsylvania, Pentec Health started as a focused provider of Intradialytic Parenteral Nutrition (IDPN) and Intraperitoneal Parenteral Nutrition (IPN) therapies for dialysis patients. Today, the company has grown into a national leader in clinical nutrition and specialty care, covering everything from renal nutrition to intrathecal home infusion therapy for chronic pain.
The company currently serves more than 11,000 patients nationwide, with care delivered by over 350 clinicians. That’s not a small operation. And it’s growing.
The Services Behind the Growth
What makes Pentec Health stand out from standard specialty pharmacy providers is the breadth of its clinical focus. The company operates across several care areas simultaneously:
- Renal nutrition services, including IDPN and IPN for dialysis patients with protein malnutrition
- Medical Nutrition Therapy for Chronic Kidney Disease management
- Intrathecal home infusion for patients managing chronic pain through implantable pumps
- Wound care nutrition therapy supporting non-healing wound healing
- Medical food products and low-protein foods for patients with inherited metabolic disorders and rare diseases
- Hepatic artery home infusion for cancer patients
- Prescription digital therapeutics through its newly launched Pentec Home Medical division
That last item reflects just how much the company has expanded. In March 2025, Pentec announced a partnership with Luminopia to offer FDA-cleared prescription digital therapeutic services, marking its formal entry into the digital health space.
Expansion That Backs Up the Claims
In May 2024, Pentec announced board approval for a new USP 800-compliant clean room dedicated to sterile and hazardous compounding in Pennsylvania. The company simultaneously broke ground on a 36,000-square-foot sterile compounding and specialty pharmacy facility in Gilbert, Arizona.
Under its ZOIA Healthcare brand, Pentec also opened an 11,000-square-foot FDA-registered food facility in Vancouver, Washington. This facility, combined with its HQAA-accredited DME division ZOIA Pharma, supports national distribution of medical formulas and low-protein foods for patients with metabolic disorders.
That’s three facilities, across three states, in a single announcement. For a company with $100 to $500 million in estimated annual revenue and 500 to 1,000 employees, that’s a serious commitment to physical infrastructure.
In July 2025, ZOIA Healthcare, operating as a Pentec company, acquired Lil’s Dietary, a boutique provider of medical and low-protein foods for individuals with inborn errors of metabolism, further reinforcing its position in the rare disease nutrition space.
What Sets Pentec Apart From Other Specialty Providers
Pentec holds Joint Commission accreditation and American Nurses Credentialing Center recognition with distinctions in Specialty Care Nurse Fellowship. In an industry where accreditation signals clinical rigor, these aren’t just badges. They’re markers of operational discipline.
The company’s model works because it fills a gap that most providers won’t touch. Patients with complex, multi-layered care needs often fall through the cracks between hospital discharge and home care. Pentec’s entire operating philosophy is built around closing that gap, specifically serving patients in underserved markets where standard providers either can’t or don’t operate.
Abbott Pacemaker Innovation and the Shift to Leadless Technology
If you’ve followed medical device news over the past few years, you’ve likely seen Abbott’s name attached to some of the most talked-about cardiac technology on the market. That reputation is backed by real results.
Abbott’s Cardiac Rhythm Management business reported 10% sales growth in Q2 2025, driven largely by accelerating adoption of its AVEIR leadless pacemaker systems. For context, the company’s Medical Devices division has now delivered double-digit organic sales growth for 12 consecutive quarters.
How Traditional Pacemakers Work and Why Leads Are a Problem
A conventional pacemaker sits in a surgically created pocket beneath the skin, typically near the collarbone. Flexible wires called leads run from the device through a vein into the heart chambers, delivering electrical pulses that regulate heartbeat.
The problem is those leads. They fracture over time. They create infection risks. They complicate MRI scans. And they require a surgical pocket that leaves a visible scar.
Leadless pacemakers solve this by going directly inside the heart through a minimally invasive catheter-based procedure. No wires. No pocket. No scar. The device sits entirely within the heart chamber and delivers pacing from the inside.
What Abbott’s AVEIR System Actually Offers
Abbott’s AVEIR lineup represents the current standard-bearer in leadless pacing. The family includes:
- AVEIR VR: a single-chamber ventricular leadless pacemaker with extended battery life designed to be retrieved if therapy needs change
- AVEIR AR: the world’s first and only atrial leadless pacemaker, now in its second generation (AVEIR AR2) with enhanced battery life and long-term retrievability
- AVEIR DR: a dual-chamber leadless system using Abbott’s proprietary i2i (implant-to-implant) technology, allowing two separate leadless devices to communicate wirelessly beat-to-beat
That last one is genuinely significant. Prior to the AVEIR DR’s 2023 FDA approval, getting two leadless pacemakers to communicate in real time inside the heart had never been achieved. The AVEIR DR solved it with synchronized pacing between a device placed in the right atrium and one in the right ventricle.
The clinical numbers back the performance. The AVEIR DR system has demonstrated a 98.3% implant success rate and 98% AV synchrony post-implant. Between Q2 2024 and Q2 2025, the number of physicians trained on AVEIR DR and the number of daily implants both doubled.
What’s Coming Next in Abbott Pacemaker Development
Abbott is pushing further. In April 2025, the company presented data from its first-in-human study of AVEIR Conduction System Pacing (CSP), a leadless pacemaker designed to target the left bundle branch area (LBBAP) of the heart. The goal is to restore more natural cardiac conduction patterns.
Results showed 100% implant success in 30 patients, with 90% achieving left bundle branch pacing. The company has since initiated the ASCEND CSP pivotal trial across 70 global sites and up to 414 patients.
Both the AVEIR CSP leadless pacemaker system and the CSP ICD lead received FDA Breakthrough Device Designations in 2024, which accelerates the review timeline and signals that FDA sees these technologies as addressing genuine unmet medical needs.
For broader context, the global cardiac pacing market is expected to grow at a compound annual growth rate of 6.2% through 2030, driven by aging populations and rising rates of bradycardia and heart block. Abbott is positioned at the front of that wave, not behind it.
Atomwise and the AI-Driven Reinvention of Drug Discovery
Drug discovery has always been a numbers game weighted against success. Finding a molecule that works against a specific disease target, doesn’t cause serious side effects, and can be manufactured reliably typically takes 10 to 15 years and costs billions of dollars. Most candidates fail in clinical trials after years of development.
Atomwise exists to change those odds using artificial intelligence.
AtomNet and the Technology Behind It
Founded on the premise that structure-based drug design can be made faster and more accurate using deep learning, Atomwise built a platform called AtomNet. The system analyzes the three-dimensional structure of proteins and disease targets to predict which small molecules are most likely to bind effectively.
What makes it different from traditional high-throughput screening is scale and speed. Conventional high-throughput screening averages hit rates between 0.01% and 0.1%. AtomNet achieves prospective hit rates between 5.3% and 7.6%, representing a 50 to 760-fold improvement over the baseline. The platform searches a proprietary library of more than three trillion synthesizable compounds.
In April 2024, Atomwise published results from its landmark AIMS (Artificial Intelligence Molecule Screening) project, which screened 318 targets in collaboration with more than 250 academic labs across 30 countries. AtomNet identified structurally novel hits for 235 of those 318 targets, with the paper carrying more than 600 authors. It remains one of the largest demonstrations of AI-driven drug discovery at scale.
Partnerships and Pipeline Progress
Atomwise isn’t just running academic experiments. The company has built serious commercial traction.
In 2022, Atomwise signed a strategic multi-target research collaboration with Sanofi, one of the world’s largest pharmaceutical companies. Under the deal, Sanofi paid a $20 million upfront payment for computational discovery across up to five drug targets. Atomwise is eligible for over $1 billion in milestone payments and tiered royalties if products advance from that collaboration.
The company has also raised $219 million in total funding, including a $125 million Series C round in 2024 to 2025, with pharmaceutical industry veteran Steve Worland appointed as CEO to drive clinical-stage progression.
The most advanced asset is a TYK2 inhibitor program for inflammatory and autoimmune diseases, currently in IND-enabling studies. TYK2 is a validated target, and Atomwise’s version of the inhibitor occupies different chemical space than approved competitors, potentially offering selectivity advantages.
In late 2025, Atomwise rebranded its operations under the name Numerion Labs, consolidating its APEX ultra-fast virtual screening technology and inflammatory disease programs under the new identity. The underlying technology, team, and programs remain continuous under the new name.
AI Drug Discovery as an Industry Force
Atomwise doesn’t operate in isolation. The broader AI drug discovery market was valued at $1.72 billion in 2024 and is projected to reach $8.53 billion by 2030, growing at a compound annual rate of 30.59%. North America leads with over 43% of global market share.
Other players like Insilico Medicine, Recursion Pharmaceuticals, and BenevolentAI are advancing their own pipelines through clinical stages, but Atomwise’s strength in structure-based small molecule discovery gives it a specific technical niche that complements rather than directly competes with generative chemistry platforms.
The critical metric to watch: can AI-originated drugs actually succeed in human trials? The early signs from the broader field are encouraging. Insilico Medicine published positive Phase IIa results for an AI-discovered drug in idiopathic pulmonary fibrosis in June 2025, representing the first clinical validation of an end-to-end AI-discovered compound. Atomwise’s TYK2 program aims to follow a similar path.
The Broader Pattern Connecting These Three Companies
Pentec Health, Abbott, and Atomwise look unrelated on the surface. One is a specialty pharmacy and clinical nutrition provider. One is a global medical devices giant. One is an AI drug discovery startup. But the growth patterns they represent share a common thread.
Each company is winning by doing something that broader markets find too hard, too niche, or too expensive to build from scratch. Pentec focuses on complex care that other providers avoid. Abbott targets a surgical challenge, leadless dual-chamber pacing, that competitors said was technically impossible not long ago. Atomwise attacks the drug targets that traditional chemistry can’t reliably reach.
They’re not competing. They’re each advancing a different frontier of the same larger story: healthcare is becoming more precise, more targeted, and more capable of treating conditions that were previously left underserved or untreated.
That pattern drives their growth because unmet need is the most durable market you can build a business around.
Frequently Asked Questions About Pentec Health, Abbott Pacemaker, and Atomwise
What does Pentec Health specialize in?
Pentec Health specializes in clinical nutrition and specialty care pharmacy services for patients with complex conditions. Its core areas include renal nutrition for dialysis patients, intrathecal home infusion for chronic pain management, wound care nutrition, and medical food products for rare metabolic disorders. The company serves more than 11,000 patients nationwide.
Is Pentec Health a publicly traded company?
Pentec Health is privately held. It was acquired by Wellspring Capital Management, a New York-based middle-market private equity firm, in October 2021. Wellspring focuses on healthcare services companies with strong clinical differentiation and market positions in underserved niches.
What is the Abbott AVEIR pacemaker and how is it different from traditional pacemakers?
The Abbott AVEIR is a leadless pacemaker system that is implanted directly inside the heart through a minimally invasive catheter-based procedure. Unlike conventional pacemakers, it requires no surgical chest pocket, no lead wires, and leaves no visible scar. The AVEIR DR version allows two separate leadless devices to communicate wirelessly beat-to-beat inside the heart, enabling dual-chamber pacing without leads for the first time in the industry.
How small is the Abbott AVEIR leadless pacemaker?
The AVEIR leadless pacemaker is smaller than a standard AAA battery. Once implanted directly into the heart, it is not visible to the eye and leaves no external scar. Despite its small size, it delivers full pacing capability including rate-modulated therapy and, in the dual-chamber configuration, synchronized beat-to-beat communication between two co-implanted devices.
What is Atomwise and how does its drug discovery technology work?
Atomwise is an AI drug discovery company that uses its AtomNet deep learning platform to predict which small molecules are most likely to bind to specific disease targets. The platform searches a library of more than three trillion synthesizable compounds using three-dimensional protein structure analysis. This approach achieves hit rates 50 to 760 times higher than traditional high-throughput screening methods.
Did Atomwise change its name?
Yes. In late 2025, Atomwise rebranded its operations under the name Numerion Labs. The underlying technology, scientific team, and drug programs, including the AtomNet platform and the TYK2 inflammatory disease pipeline, continue under the new name with a strategic focus on ultra-fast virtual screening and immune disease programs.
What is Atomwise’s partnership with Sanofi?
In 2022, Atomwise entered a strategic multi-target research collaboration with Sanofi for computational drug discovery across up to five drug targets. Sanofi paid $20 million upfront, and Atomwise is eligible for over $1 billion in milestone and royalty payments if products successfully advance from the partnership.
How does Pentec Health’s ZOIA Healthcare division work?
ZOIA Healthcare is a Pentec Health subsidiary that focuses on medical food distribution and rare disease nutrition. It operates an FDA-registered food facility in Vancouver, Washington, and an HQAA-accredited DME division called ZOIA Pharma. In July 2025, ZOIA acquired Lil’s Dietary, a boutique provider of low-protein foods for patients with inborn errors of metabolism, expanding its rare disease product line further.
What accreditations does Pentec Health hold?
Pentec Health holds Joint Commission accreditation and American Nurses Credentialing Center recognition with distinctions in Specialty Care Nurse Fellowship. The company is also accredited through HQAA for its DME operations under the ZOIA Pharma brand.
What is the global market size for AI drug discovery?
The AI in drug discovery market was valued at $1.72 billion in 2024 and is projected to reach $8.53 billion by 2030, representing a compound annual growth rate of 30.59%. North America holds over 43% of global market share, driven by advanced research infrastructure and major pharmaceutical and biotech investment.
Where Each of These Companies Goes From Here
Pentec Health’s trajectory points toward continued service expansion. The company’s new facilities in Arizona, Pennsylvania, and Washington give it compounding and distribution capacity that positions it to serve both new therapeutic areas and new geographies. The Pentec Home Medical division, with its prescription digital therapeutic services, represents a direct bet on the growing intersection of pharmacy and software-based care.
Abbott’s pacemaker division has a clear near-term catalyst in the ASCEND CSP pivotal trial. If that trial leads to FDA approval by 2026 for conduction system pacing technology, it expands an already growing product line into a market segment where Abbott currently holds no approved product. With 12 consecutive quarters of double-digit medical device sales growth, the momentum is already there.
Atomwise, now operating as Numerion Labs, needs its TYK2 inhibitor program to advance into human trials to validate the AI-first drug discovery model commercially. The industry context is favorable: the first wave of AI-designed drugs is reaching clinical stages across multiple companies, and success in any one of them shifts investor and pharma partner confidence in the whole sector.
For more on companies changing the way healthcare works at a systems level, explore Reuterings.com‘s coverage of health and fitness trends, medical technology, and the emerging companies building the next generation of patient care.
